Zoladex and Casodex
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Advanced Prostate Cancer
Conditions
Advanced Prostate Cancer
Trial Timeline
Jan 28, 2021 → Nov 9, 2022
NCT ID
NCT03971110About Zoladex and Casodex
Zoladex and Casodex is a approved stage product being developed by AstraZeneca for Advanced Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03971110. Target conditions include Advanced Prostate Cancer.
What happened to similar drugs?
15 of 20 similar drugs in Advanced Prostate Cancer were approved
Approved (15) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03971110 | Approved | Terminated |
Competing Products
20 competing products in Advanced Prostate Cancer